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METHYLATION MARKERS IN 
HEPATOCELLULAR CARCINOMA 
AVINASH GAVICHARLA 
                                                  ABSTRACT 
Hepatocellular Carcinoma is one of the major causes for mortality in the world and is 
usually asymptomatic until late stage decreasing the survival rate. There is an increase of 
incidence every year and current diagnostic and prognostic bio markers like AFP have 
their limitations in the wider context. Therefore, it is important to develop novel 
biomarkers.  
The aim of the Research is to understand the cytosine methylation and investigate the role 
of the p16 and SLIT-2 genes as biomarkers in Hepatocellular Carcinoma. The 
methylation profiles of the genes were assessed on bisulfite modified DNA samples with 
the aid of Real time PCR. The specificity and sensitivity of the genes were calculated 
using the Standard Curve Analysis and specificity was determined by the ability to 
differentiate between methylated and unmethylated DNA. The sensitivity was determined 
by using different percentages of methylated and unmethylated DNA. This study 
identifies SLIT-2 as a potential biomarker and show the role of DNA methylation as an 
important part of hepato-carcinogenesis and its importance as a Biomarker. 
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CHAPTER I 
INTRODUCTION 
1.1 Epigenetics 
The term “Epi” means “on top off,” which explains the word “epigenetics” as another 
layer of information or a secondary layer of information on top of the genetic code. 
Epigenetics is nothing but the study of stable heritable changes in the genotype or the 
cellular phenotype which alters the final outcome without changing the underlying DNA 
sequences. Epigenetic studies are the studies of covalent and non-covalent modifications 
of DNA and the relative mechanisms which affect the overall chromatin structure. 
However, two important features distinguish the genetic alterations from the epigenetic 
changes namely, the gradual appearance and the reversibility of the epigenetic events. 
These two important features enables the epigenetic alterations a target for the therapeutic 
intervention and development of the strategies to prevent them.  
The epigenetic information that can be inherited by the chromosomes can be categorized 
into three aspects namely (1), DNA methylation which occurs at the fifth carbon position 
of the cytosine pyrimidine ring with the addition of a methyl group via a 
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methyltransferase enzyme usually at the CpG dinucleotides, Epigenetic alterations 
involving the Ribonucleic acid in the form of non-coding RNA or RNA interference and 
lastly histone post translational modifications like acetylation, methylation, ubiquination 
which occur at the N-terminal part of the tail of the histones which form a key part of the 
mechanisms and any deregulations of them leads to malignancies. 
1.2 DNA Methylation 
DNA Methylation is the covalent chemical modification resulting in addition of methyl 
group at 5th carbon position of the cytosine ring. DNA methylation is a naturally 
occurring event in both prokaryotes and eukaryotes. In prokaryotes, they majorly play a 
role of protection of the host DNA from restriction endonucleases produced to destroy 
foreign DNA. However, they have a complicated role in eukaryotes like gene imprinting, 
X chromosome Inactivation, embryonic development and cell cycle regulation. When we 
consider the classic view of DNA methylation, it varies according to the developmental 
stages namely pre and post developmental processes. The former pattern associates the 
methylation processes into active or passive methylation whereas the latter involves its 
maintenance based on DNMT’s (2). DNA methylation errors are potentially reversible 
and as a result aid in Pharmacological changes. 
1.2.1 DNA methylation and Carcinogenesis 
Aberrant changes in the DNA methylation promote disease state. Aberrant DNA 
methylation is found in two distinct forms namely hyper methylation and DNA 
hypomethylation. Hyper methylation is usually associated with the gene inactivation 
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involving CpG islands and hypo methylation involving repeated DNA sequences of 
nuclear elements (3). These two processes are independent processes (4). 
1.2.1.1 Hyper methylation in Cancer 
It is one of the most studied epigenetic changes in cancer. DNA hyper methylation 
typically occurs in the CpG islands. The promoter site and transcription site are included 
within the CpG islands and when hyper methylation occurs at these islands, the 
expression of gene is totally repressed leading to gene inactivation (5).  
CpG Islands 
DNA is made up of four bases namely Adenine, Guanine, Cytosine and Thymine. Among 
these four bases, the numbers of dinucleotide combinations possible are 16 (6). Out of 
which, the cytosine methylation occurs in 5’CG 3’ dinucleotide combination. Based on 
the percentage of these combinations, the frequency of these dinucleotides should be 10% 
but only occur around 5% (7). Methylation isn’t uniform through the human genome, 
containing both methylated and unmethylated segments. Unlike the rest of the genome, 
CpG islands are interspaced on an average of 100kb and ranging up to 5kb are smaller 
regions of unmethylated DNA which are GC rich, Guanine Adenine content above 0.5 
and having distinctive properties without any suppression of the occurrence of 
dinucleotide CpG. It is known that human genome contains around 29000 CpG islands 
and is associated with about 60% of mammalian genes, mostly in promoter and first exon 
region of genes. In normal, healthy tissues CpG islands are unmethylated but these are 
methylated to various extents in cancer (8). 
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There are different protective mechanisms that prevent the hyper methylation at these 
CpG islands like demethylation, changes in chromatin structure, active transcription and 
timing of replication (6). 
 
 
 
Figure 1.1:  The methylation state of a gene is equilibrium of methylation and 
demethylation reactions (9). 
As the figure 1.1 indicates, DNA methylation is a reversible reaction and the active 
chromatin recruits DNA demethylases, the enzymes responsible for DNA demethylation 
and inactive chromatin recruits DNMT’s. Therefore, if the chromatin structure is 
maintained DNA methylation is maintained. Hyper methylation is region specific and the 
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local changes around this specific region of genes inhibit them from interacting with the 
demethylases, protecting them from demethylation. 
1.2.1.2 Global Hypo methylation in Cancer 
Global DNA hypo methylation was the first identified epigenetic event in cancer. Hypo 
methylation is the loss of methylation and this loss is quite predominantly seen as they 
are quantitative in nature and affect a variety of repetitive sequences which are dispersed 
throughout the genome. Usually, the pericentric regions of chromosome 1-16 are hypo 
methylated, with most cases occurring in regions with sparsely distributed CG sequences. 
Hypo methylation plays a role in cancer by various mechanisms like instability of the 
chromosome (10), activation of the long interspread nuclear elements called 
retrotransposons in the genome (11). Hypo methylation of these transposons, which are 
usually latent, may lead to oncogenesis by transcriptional activation and sometimes may 
express themselves on the adjacent genes (12). 
1.3 DNA Methylation Machinery 
Based on the methylation patterns of CpG dinucleotides on both strands, DNA 
methylation can be either Denovo Methylation or Maintenance Methylation. Denovo 
Methylation occurs, when the CpG dinucleotides on both the strands are unmethylated 
and has an important role in cell growth, differentiation and tumor genesis.  Maintenance 
methylation occurs when CpG dinucleotides on only one strand are methylated (9). It 
mainly copies the DNA methylation patterns but does not introduce any different 
methylation patterns. 
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Figure 1.2: Epigenetics provides a new generation of oncogene and tumor-
suppressor genes 
As the figure 1.2 suggests,  DNA methylation machinery can be classified into two ways 
namely, transcriptional repressor machinery to the corresponding promoter CpG island 
which contribute to tumorigenesis by silencing of TSG’s and the Transcriptional 
Activation machinery for the active expression of the oncogene. 
Transcriptional Repressor Machinery include DNA methyl transferases, Methyl CpG 
Binding proteins, histone methyltransferases for lysine 9 of histone H3 (HMT K9 H3), 
histone deacetylases and polycomb. Transcriptional Activator machinery includes 
HAT’s, HMT’s and others. Of these, epigenetic machinery DNMT’s, MBD’s and HAT’s 
play an important role in DNA methylation. 
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1.3.1 DNA Methyltransferases (DNMTs) 
DNA methyl transferases are the enzymes that catalyze the transfer of the methyl group 
from the methyl donor S-adenosyl methionine onto the DNA and release S-adenosyl 
homocysteine (13). DNMTs are the critical proteins involved in establishing proper 
control of epigenetic information. In mammals, four different types of DNMTs are seen 
DNMT1, DNMT2, DNMT3a and DNMT3b. The balance of DNMT’s is very important 
to prevent cell transformation. The DNMT’s in conjugation with accessory proteins like 
DNMT3L are mainly responsible for DNA methylation at various stages like 
embryogenesis and development of somatic tissue (14). 
DNMT 1 is the most abundantly found among DNA methyl transferases. It is useful in 
maintaining the post replicative DNA methylation patterns. It is useful for maintaining 
the methylation pattern during cell division. The DNA Methylation patterns are passed on 
from the parental strand to daughter cells and DNMT1 maintains this maintenance 
methylation (15). It also plays an important part in Denovo methylation (16). They 
maintain gene silencing in cancer cells, by cooperative interactions between DNMTS 
especially DNMT1 and DNMT3b. DNMT 2, is not involved much in DNA methylation. 
However, it can contribute to cancer through different pathways related to RNA. 
DNMT3b is mainly involved in Denovo methylation .It is also a part of several 
complexes. It inhibits gene expression by forming a transcription repressive complex.  
DNMT3B leads to demethylation when it is deleted and with DNMT1 and maintain the 
global methylation (17). 
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1.3.2 Methyl-CpG binding domain proteins 
MBD proteins are considered interpreters of DNA methylation. They are important 
between DNA methylation and genes involved in histone modifications. All of them bind 
to the CpG sites with the exception of MBD3 (18). Twelve different types of Methyl CpG 
proteins have been identified of which MBD1, MBD2, MBD3, MBD4 and MeCP2 are 
the most important members (17). They play a role in the pathophysiology by a number 
of mechanisms. They associate with the CpG island promoters of the Tumor suppressor 
genes and lead to transcriptional silencing. MBD4 is different when compared to other 
MBDs as it is a thymine glycolase and it helps in DNA repair protein, as the Glycolase 
domain removes thymidine from T: G mismatches (19). 
1.3.3 Histone Modification Enzymes 
Histones are used to store the epigenetic information through modifications of the amino 
terminal protruding tails. These modifications generally include acetylation, 
phosphorylation, and methylation. Histone Modification Enzymes involved are histone 
acetyl transferases (HATs), Histone methyltransferases (HMTs) and histone deacetylases 
(HDACs). HATs are involved in the Acetylation of histone lysine’s and HMTs aid in the 
deacetylation. 
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CHAPTER II 
HEPATOCELLULAR CARCINOMA 
2.1 Introduction 
Primary Liver cancer can be distinguished into three main types namely Hepatocellular 
Carcinoma which occurs from Hepatocytes, Duct cell Carcinoma and cholangiohepatoma 
which occurs from intrahepatic bile ducts. Clinically there is not much difference 
between them since they spread throughout the liver (20). Primary Liver Cancer is unique 
when compared to all the malignancies because of its worldwide distribution, association 
with cirrhosis, spontaneity of the tumor and inherent difficulties (21). Primary Liver 
Cancer is the fifth most common cancer in the world and second rated cancer with most 
deaths (22). Hepatocytes, the parenchymatous cells which are chiefly responsible for its 
functioning and their uncontrolled division leads to primary liver cancer in most cases. 
Hepatocellular Carcinoma is the predominant type of liver cancer and also called as 
hepatoma based on its occurrence and it accounts for about 85-90% primary liver cancers 
(23). HCC is the fifth most common cancer in men and eighth most common in women. 
Hepatocellular Carcinoma is usually asymptomatic, with Cirrhosis being the major 
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condition present in about 80-90% of them and by the time of diagnosis it is usually 
advanced leaving with a 5 year survival rate. Hepatocellular Carcinoma have different 
growth patterns with some starting as single tumor and grows large before spreading and 
others appear as small spots in various areas. It is very important to diagnosis HCC early 
to improve the survival rate. 
2.2 Epidemiology of Hepatocellular Carcinoma: 
Several epidemiological factors like age, sex, ethnicity, distribution of risk factors 
influence HCC. Geographically speaking, greater number of the cases of HCC is found 
either in sub-Saharan or Asian populations. In United States, the rates of incidence 
increased at a two-fold rate between 1985 and 2002. When you compare ethnicity among 
different regions, Asians are twice susceptible to HCC than Americans. This might 
depend on the differences in attainment of the risk factors of HCC. The age is an 
interdependent epidemiological factor based on various factors like sex, age of infection 
and so on. Hepatitis B Virus usually infects at younger age when compared to HCV. 
Throughout the world, age of incidence of HCC in men is approximately 5 years lower 
when compared to that of women. Sex of an individual highly influences the incidence 
rate because, throughout the ratio of incidence between male and female is either two 
fold or four fold with male dominating. This again might be due to various factors like 
exposure to viral factors, alcoholism and smoking with largest difference in ratios seen in 
European populations. Studies conducted state that men have higher BMI and higher 
level of androgenic hormones might be a reason for higher incidence of HCC. HBV and 
HCV are the two most dominant risk factors in HCC. However their distribution varies 
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from place to place. Globally, HBV risk factor is more dominant. In places like Japan 
HCV show greater dominance than HBV. 
2.3 Risk Factors for Hepatocellular Carcinoma 
The risk factors of HCC can broadly be categorized into pathological factors, 
physiological factors, exposure to environmental toxins and dietary factors (23). The 
physiological factors like geography, age and sex are mostly patterns of the pathological 
factors mostly HCV, HBV and alcohol liver disease (24). The physiological factors for 
HCC incidence increase with age and males have greater chance of Incidence than 
females. The pathological factors can be categorized into Hepatitis B virus and Hepatitis 
C virus. Liver Cirrhosis can be considered to be the main precursor because about 70% 
have HBV related Cirrhosis when compared to the 20% HCV related Cirrhosis (25). 
Various studies show that incidence of HCC in patients with chronic Hepatitis or 
Cirrhosis is greater when compared to the patients with normal transaminases (26).HCV 
does not play a direct role in HCC. However it leads to development of Cancer through 
Cirrhosis. Exposure to environmental Toxins like Aflatoxin, which is a product of 
Aspergillus fungus, on the legume crops is less developing countries and on dietary 
intake of them leads to development of HCC (27) (28). Alcohol does not have any 
particular mutagenic properties. Effect of Consumption of Alcohol is usually dose 
dependent and leading to HCC through Cirrhosis. It was proved in a Cirrhosis study that 
chances of HCC are 13 times greater in people consuming alcohol when compared to 
people who stay away from it (29). Smoking is also an important factor in HCC, with 
studies showing a contribution of about 50% in HCC (30). Few of the rarer factors which 
influence HCC are hemochromatosis which is a genetic factor and few metabolic diseases 
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like Diabetes type-II, glycogen storage disease type 1 and alpha-1 antitrypsin deficiency 
(31). 
2.4 Molecular Mechanisms of Hepato- Carcinogenesis 
The pathophysiology of HCC is mainly based upon cirrhosis. Different molecular 
mechanisms inhibit the regenerative capacity of the liver at cirrhotic stage and these 
mechanisms tend to increase the rate of carcinogenesis at cirrhotic stage. They can be 
classified into cell intrinsic alterations and cell extrinsic alterations (23). Cell intrinsic 
alterations involved are the shortening of the length of telomere which restricts the 
proliferation of hepatocytes (32) (33), thereby leading to induction of chromosomal 
fusion by activating DNA repair pathways (34) (35). Cell extrinsic alterations involved 
mainly are the decrease in the proliferation of the primary liver cells and changes in the 
micro and macro environment, thereby promoting risk of cancer. 
 
Figure: 2.1 Molecular Mechanisms of Hepatocellular Carcinoma at the cirrhotic 
stage (23) 
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2.5 Staging and Diagnosis of Hepatocellular Carcinoma 
The method developed by Okuda et al is the most commonly used staging system 
presently. This system evaluates the albumin levels, size of the tumors and concentration 
of bilirubin of patients. However, it is ineffective at early stages of the disease. Several 
prognostic staging systems are currently in clinical use like Barcelona Clinic Liver 
Cancer, Tumor node metastasis which although advanced does not consider underlying 
Cirrhosis. Although they all differ on the way of evaluation, they are useful in better 
understanding of diagnosis. 
HCC Tumor is categorized by AJCC, into various stages based on the clinical status of 
the patient, the size of the tumor, the number of lesions. Stage I and II with the tumor 
showing some Invasiveness in the blood vessels and forming single to multiple tumors. In 
stage IIIa, multiple tumors are formed which tend to increase in size and these tumors 
extend to the hepatic vein by stage IIIb and reach the visceral peritoneum by Stage IIIc. 
In stage IVa and IV b leads to initially regional to distant metastasis (36) (37). 
Diagnosis of HCC involves differential Diagnosis of well differentiated HCCs from 
lesions and poorly differentiated HCCs from malignancies similar to HCC outside liver. 
Usually well differentiated HCC’s from dysplastic nodules and poorly differentiated 
HCC’s from metastatic tumors, chlorangiosarcoma (38). Diagnosis is mostly possible 
only when symptoms like weight loss or sometimes much more severe like liver failure 
are seen and usually suggesting presence of tumored liver (39). Some of the common 
methods of diagnosis include imaging like CT scan, MRI. The noninvasive nature, fewer 
costs make imaging more preferable though they are late in detecting only until large 
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tumors are formed (40). The confirmation of the pathology of HCC play a role in 
diagnosis and biopsy is a method of doing it. However, it also chances of spreading the 
disease. 
2.6 Current Treatment options 
Surgical resection is the preferred method for very early HCC. It is usually indicated in 
patients without cirrhosis and portal hypertension. Patients with preserved liver function 
are resected. The only problem it faces is recurrence. However in combination with 
adjuvant therapy it can be controlled. Liver transplantation is another method for 
treatment of early HCC and is suitable for patients without proper functioning of liver 
and any extra hepatic spread or vascular invasion and nodules of size less than 5cm. 
However, the demand of livers and waiting time is a problem. If the waiting time is 
greater than 12 months 25% more chances of tumor being spread. Ablation is a method 
with similar recurrence chances and survival rates when compared to Surgical Resection. 
It is effective when nodules are below 2cm (41). Percutaneous ethanol injection has been 
the most successful technique of ablation with little adverse effects. It is time taking and 
ineffective in tumors larger than 3cm. RFA solves most of these issues of the PEI with 
greater side effects (39). Some other common ablation techniques are microwave and 
cryoablation. For patients, with Intermediate HCC and multi nodular tumors without any 
invasion and extra hepatic spread, Transcatheter Arterial Chemo embolization and     
Trans-arterial embolization with a radioactive isotope Y90 was used. For patients with 
Advanced HCC, systemic therapy with Sorafenib, a multi kinase inhibitor is mostly used 
and few others like Sunitinib, brivonib and being investigated (42) (43). 
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2.7 Current Trends in Research of Biomarkers for Hepatocellular Carcinoma 
HCC is usually asymptomatic and biomarkers therefore act as measurement tools for 
diagnosis of the disease, its progression and help to target a proper therapeutic treatment. 
Different types of Biomarkers are presently used worldwide. Alpha–Feto protein is the 
most commonly used biomarker presently and can be called as a gold standard, it is pretty 
much useful in patients with known risk factors as its increase is directly in 
correspondence with the development of HCC (44) (45). However it does not correlate 
much to the prognostic factors of HCC. 
Different types of Immuno Histochemistry markers are useful as diagnostic markers as 
they use immunochemical staining to distinguishing well differentiated HCC. Some of 
them are HSP70, Glypican 3. These usually appear and reappear during tumor genesis 
and usually used in combinations (46). Some of the IHC markers used in prognosis are 
Ki67, Survivin and E-Cadherin. Enzymes and Iso-enzymes used as biomarkers like Des-
Gamma-Carboxy Prothrombin which when used with AFP increases the sensitivity, 
Gamma Glutamyl Tranferase also is used in combinations with AFP and DCP increases 
the sensitivity (47). Several growth factors like fibroblast growth factor, epidermal 
growth factor receptor family and hepatocyte Growth Factor are used. Hepatocyte 
Growth factor plays an active role as biomarker in prognosis and recurrence. It plays a 
role in HCC through the pancrine system involving the receptor c-met.  Circulating 
Nucleic acids mainly mRNA, like GGT mRNA, IGF-2 mRNA are analyzed in various 
pathological and physiological conditions. Micro RNAs provide new insights into HCC 
carcinogenesis and therefore used in prognosis and diagnosis of the disease.  
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Depending upon the etiology of the HCC and the molecular abnormalities make it pretty 
difficult to find a biomarker with good specificity and sensitivity. These are the currently 
used markers based on the different molecular pathways of HCC and these show great 
amount of significance and on further research can be used to improve the prognostic 
values and assist in determining the proper mode of therapy. 
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CHAPTER III 
 DNA METHYLATION ANALYSIS TECHNIQUES 
DNA methylation analysis techniques can be categorized based on chemical modification 
of molecules, the precipitation of methylated DNA by proteins which interact with the 
methylated cytosines (48). It is important to choose a protocol on the basis of several 
factors like sensitivity, cost, specificity and the desired results. In the precipitation 
techniques, complexes are formed between the proteins and the methylated DNA. These 
proteins bind and enrich the methylated DNA. Several protocols use different proteins, as 
in MIRA protocol, a complex of MBDs with glutathione –S-transferase isolates the 
methylated DNA (49). MBD2 and MeCP2 (methyl binding domain of MBD2 are the 
most commonly used in isolating methylated DNA (50). MBDs are not specific and are 
affected by the methylation density of DNA (51). Lack of Specificity and sensitivity 
limits the precipitation techniques usage. 
DNA methylation Analysis techniques using methylation sensitive restriction enzymes 
which are sensitive to the cytosine methylation in CpG can be used (52). This method 
involves the division of DNA into two samples and then digests one with enzyme 
sensitive to the DNA and one without sensitive to DNA methylation and later the missing 
cuts of enzymes and methylation are compared (48). However, the incomplete digestion, 
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buffer conditions, over dependence on the sequence of Restriction site and the 
distribution limits its sensitivity. 
Microarrays techniques are generally used in combination with few analysis techniques. 
High resolution arrays like oligonucleotide arrays have been used in analysis (53). Some 
of the arrays used are SNP’s (54). They cannot quantify the methylation level accurately 
and therefore acts as a drawback. Methylation Bead chip technology is the currently used 
microarray technique and it can effectively overcome the drawbacks (55). The techniques 
which focus on the alterations of DNA depend mainly on the conversion of the 
methylated DNA by the treatment with sodium bisulfite. The figure 3.1 gives a small 
description of methods of the DNA Methylation Analysis techniques presently used. 
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Figure 3.1:  DNA Methylation Analysis Techniques 
3.1 Methylation-Specific PCR (MSP) 
MSP was one of the early changes which involved Bisulfite Conversion. It was 
introduced by Herman and colleagues (56). It is a standard PCR reaction used to analyze 
the methylation status of CpG islands. In this reaction, distinct methylation primer sets 
for the sequence of interest are used like, the unmethylated primers specific for the 
unmethylated DNA whereas the methylated primer specific for methylated DNA. The 
unmethylated cytosines are converted to thymines and methylated cytosines are 
unconverted and therefore the primers designed should include CpGs of interest. 
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When compared to other DNA methylation techniques MSP exhibits several advantages 
based on the simplicity of the procedure, time taken for and lack of need of any specific 
equipment. It is also less expensive and the presence of larger number of the CpG sites in 
the CpG islands. These factors aid the use of MSP in larger number of samples with a 
better sensitivity. It is also used in the prevention of unwanted non tumor cells in the 
sample, if a uniformly opposite pattern is observed by the tumor cells thereby increasing 
the detection (57). However it is difficult to obtain good capability as it is a very 
laborious process. 
It depends on various critical factors like Bisulfite Conversion, designing of the primer 
and PCR. 
3.1.1 Bisulfite conversion 
The existence of 5-methyl cytosine in the DNA is a very important area of study in the 
present genomic era. One of the most important Analytical method to determine the sites 
of the 5-Mc in the genome is the bisulfite modification of the genome (58). To 
understand the role of DNA methylation in various disease states it is very important to 
quantify and detect the 5-Mc and bisulfite modification is considered as a very efficient 
method and a gold standard in doing so (59). 
Principle of Bisulfite Conversion 
It is based on the selective reactivity of sodium bisulfite with cytosines and methylated 
cytosines. The chemistry of cytosine deamination involves three steps namely, 
Sulfonation which involves addition of bisulfite to the 5, 6 bond of the cytosine in the 
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presence of acidic pH, hydrolytic deamination which is an irreversible conversion of 
cytosine bisulfite derivative to Uracil bisulfite derivative aided by a free radical 
scavengers to prevent any oxidization. This is followed by the alkali desulfonation of the 
Uracil bisulfite derivative to Uracil in the presence of an alkali to decrease the pH and aid 
in desulfonation (60). Bisulfite treatment deaminates cytosine to Uracil and leave 5-
methylcytosine unchanged. One of the major advantage of this method is the integrity of 
the DNA is maintained and thus enable various techniques for amplifying or analyzing 
DNA to be performed on the bisulfite modified DNA, thereby can startup with low 
Concentrations of DNA (48). 
 
 
Figure 3.2: Bisulfite Mediated Conversion of Cytosine to Uracil (61) 
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The efficiency of the bisulfite conversion is dependent on the following errors like (62), 
failed conversion when unmethylated cytosine do not undergo deamination and as a 
result it appears methylated and thus gives an increased estimation of methylation and 
often it can be corrected by increasing the time of bisulfite treatment or by increasing the 
number of denaturation steps (63), by doing so can also prevent the renaturation of 
sample DNA. Inappropriate conversion is another important problem which occurs when 
methylated cytosine undergo deamination yielding thymine and they like Uracil pair up 
with adenine during PCR and are misinterpreted as unmethylated leading to 
underestimation of the methylation density (64). Depurination during the time of 
conversion is another notable problem by failing of enzymatic reactions when using 
negligible amounts of DNA (65). Degradation of template DNA is a very common side 
effect seen and it affects the detection limit of method but how much of DNA is lost 
during the reaction is not known. Usually, at a temperature of 95 degree Celsius DNA 
degrades rapidly and thus higher temperatures are preferred only if sufficient amount of 
DNA is available and it is always advisable to keep the incubation time as low as possible 
since it is evident that the longer the incubation time greater the degradation (64). 
However, DNA methylation Analysis on the basis of bisulfite modification are performed 
on a larger spectrum and many methods of amplification enable a bisulfite converted 
DNA concentration of 50ng sufficient and thus enabled the design of various techniques 
based on bisulfite conversion. 
3.1.2 Primer Design 
The primer design is a very important parameter and is essential in determining the 
methylation status of a gene promoter. Some of the important parameters to be taken care 
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while designing a primer are, they should be at a length of 23-24 bp to achieve desired 
gene specific annealing (66). Exact Annealing temperature of the primer has to be 
determined, because low stringency leads to mismatching and MSP depends on specific 
annealing to the DNA. Amplification of the unconverted CpG dinucleotide which is 
unmethylated may show greater methylation levels. Therefore, the primers should be 
designed to be specific to Bisulfite modified DNA and also contain few non CpG 
cytosines in the original template (48). 
3.2 Applications of MSP 
Various methods of MSP have been developed to increase the sensitivity of detection of 
MSP for the methylated DNA. Nested MSP is on such method which is more sensitive 
and allows detection of very small quantities of DNA. However, problems like 
renaturation, incomplete bisulfite conversion and lack of accurate information about the 
single strand are seen (67) (68). Quantitative MSP is useful to quantify the number of 
methylated alleles. It is mainly advantageous as it does not involve steps like gel 
electrophoresis, enabling it’s us as an important tool in fast screening (69). 
It is very difficult to find out the exact timing of the methylation changes by MSP. To 
prevent these types of issues ISH have been used. It was used in combination with MSP 
and aid in the detection of methylated DNA on tissue slides (70).  It is used to examining 
the progress of tumor, CpG island methylation and gene expression. HPLC is also used 
and various forms of HPLC like Denaturing HPLC are used in combination with MSP 
and they detect methylation patterns based on the denaturation temperatures (66). Ion 
pair-Reverse phase HPLC was also used to distinguish between methylated and 
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unmethylated with the help of deoxynucleotides (71). Denaturing Gradient Gel 
electrophoresis is a method based on the thermal stability useful to detect the overall 
methylation differences and it is the first study to differentiate between methylated, hemi 
methylated and unmethylated sites (72) (73). These are some of the methods which use 
MSP as a combination and try to increase the sensitivity of the MSP and aid in better 
detection between methylated and unmethylated DNA. 
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CHAPTER IV 
BIOMARKERS 
A biomarker can be defined as, an indicator used to measure the normal biological 
function, pathogenicity and response to drug treatment (74). A biomarker can either be 
secreted by the malignancy itself or as a physiological response to the presence of the 
cancer. A clinical end point usually determines the efficacy and the biomarkers are 
mainly used to form an intermediate endpoint and are thus used to monitor earlier stages 
of carcinogenesis (75). Biomarkers are distinguished mainly into two types, Biomarkers 
which are used to determine the successful dosage levels required and those which are 
used to determine the progress of a disease (76). Biomarkers in cancers have 
multidimensional role (77), they serve in screening studies and diagnosis. Biomarkers 
used in screening studies usually check the existence of any premalignant conditions or 
the exposure and in diagnostic role, they are mainly used to diagnosis the presence or 
absence of cancer in a certain individual. They also constitute a role in the prevention 
trials of cancer and its treatment as they focus on various effects, like the side effects 
induced and they further focus on the toxicities rather than the desired result.
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The primary defect in Cancer is in the genomic DNA and alterations of DNA like 
translocation, mutations, aberrant DNA methylation play a major role in carcinogenesis 
and the biomarkers which can bring about these DNA alterations are used as potential 
tumor biomarkers. The use of DNA as a tumor marker has several advantages. When in 
comparison with proteins they can be amplified and therefore useful in the detection of 
minute quantities of the samples. High stability when compared to m-RNA and the 
proteins which aids its survival in adverse conditions for longer periods (78). 
4.1 DNA Methylation as a bio-marker 
The aberrant methylation of the promoter regions of genes is seen both in early as well as 
advanced cancers and when DNA with these aberrantly methylated genes is released into 
the blood serves as an indicator for the earlier detection of the cancer. This ability to 
detect cancer in its earlier phases makes DNA Methylation an important marker over 
other markers which cannot detect cancer in its earlier phases of tumorigenesis (79). The 
involvement of DNA methylation in both onset as well as progression of different 
cancers enables it to serve a dual role both as a diagnostic and a prognostic marker of 
disease. The main advantage of DNA methylation over mutations which can arise at any 
point in the gene is its site specificity thus increasing its sensitivity of detection. 
4.1.1 DNA methylation as a Diagnostic Marker 
Early diagnosis is very critical for the successful treatment of cancer. The traditional 
methods of diagnosis invasive as well as noninvasive like cytology, histopathology and 
immunohistochemistry are useful. The detection of cancer with minimal invasive 
procedure is always preferred. The changes in the marker should be specific so as to 
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differentiate the level of malignancy and assess the premalignant conditions, thereby 
diagnosis the risk level of the progression of the malignancy. 
The sensitivity and the specificity of the DNA methylation marker depends on many 
factors in cancer diagnosis namely the type of body fluid used, type of cancer studied and 
techniques involved (6). DNA methylation biomarkers can show few premalignant 
conditions which are not progressed to a level of detection detectable by other methods of 
detection by quantitative analysis of the levels before its progression to a fatal limit of 
malignancy. Some of the available diagnosis methods might show false results leading to 
further analysis and therefore costing time, money as well as psychological stress. This 
can be avoided by using DNA methylation markers in combination with other tests as a 
panel and therefore increasing the sensitivity and specificity of the screening procedures. 
4.1.2 DNA Methylation as a prognostic and predictive bio-marker 
The genes which undergo methylation at any stage of the cancer progression act as 
potential prognostic markers whereas predictive biomarkers are the markers based upon 
the therapeutic results (80). For determining the best therapeutic mode of treatment, 
patient’s response to the administered chemotherapeutic agent and survival, thereby 
allowing monitoring of various changes accordingly, these markers are utilized. Usually 
prognosis is carried on in absence of the adjuvant therapy. 
Predictive markers are usually evaluated when measurable amount of disease is usually 
seen whereas prognostic effect is usually evaluated as a control without any systemic 
treatment. Prognostic factors are mainly utilized to differentiate patients based on the 
aggressive of the disease thereby treating them accordingly by avoiding the unnecessary 
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side effects. However it is still unclear in many reports whether the predictive or the 
prognostic impact has been observed. 
4.2 p16 as a biomarker 
p16INK4 is a tumor suppressor gene which negatively regulates the cell cycle by binding 
to the cyclin-dependent kinases and inhibiting them. The p16INK4 is located on 
chromosome 9p21 and is one of the most altered genes in human cancers (81). The entry 
and progression of cells through different phases of cell cycle with the aid of cyclins 
which form complexes with group of constitutively expressed proteins called cyclin 
dependent kinases (CDKS) and P16 is a cyclin dependent kinase Inhibitor of CDK4 and 
CDK6 which participation in the cyclin dependent phosphorylation of the retinoblastoma 
protein (pRB) regulatory pathway. 
The exact mechanism of action of p16 as TSG is not clear. However, p16 is usually 
inactivated in three ways homozygous deletion, promoter methylation and point 
mutations in tumors which retain wild type Rb and ectopic expression of these cells result 
in G1 arrest causing its frequent inactivation and homozygous deletion aids not only in 
development but also in prognosis of several tumors (82).    
4.3 SLIT-2 as a biomarker 
Slit-2 is a novel tumor suppressor gene and belongs to the SLITs family which comprises 
of ECM secreted and membrane associated glycoproteins. SLIT2 and it’s another two 
members SLIT1 and SLIT-3 are the ligands for the ROBO-gene family, which are the 
receptors for interactions between axons and growth cones during neuronal development. 
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Expression of SLIT-2 in non-neuronal tissues apart from neuronal ones shows its role 
outside its neural importance.  
SLIT-2 gene maps on the chromosome 4p15.2 and it consists of a argin-laminin-
perlecan-slit conserved space motif, four leucine rich repeats, nine epidermal growth 
factors repeats and a cysteine knot (83). The interaction of SLIT-2 with ROBO-1 is 
through its leucine rich repeats. SLIT-2 has been found to have a profound role in 
tumorigenesis, invasion, metastasis and prognosis of various cancers (84). 
SLIT-2 is considered as a TSG because of its frequent inactivation in a wide variety of 
cancers due to hyper methylation of its promoter region. SLIT-2 exhibits its tumor 
suppressive effect by a modulating the beta –catenin-wnt signaling pathway. Beta-catenin 
is considered to be an oncogene and its deregulation or activation of mutations can lead 
to carcinogenesis (85). The activation of this pathway plays an important role in human 
hepatocellular carcinoma. Wnt/beta-catenin pathway plays an essential role in all phases 
of liver development like development, regeneration and maturation and is essential for 
the metabolic function of liver (86). 
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CHAPTER V 
MATERIALS AND METHODS 
5.1 Bisulfite Conversion 
Prior to the sodium bisulfite conversion, the DNA concentration was quantified by RT-
PCR amplification. Standard methylated and unmethylated genomic DNA was purchased 
for establishing the standard curve. Different concentrations of the standard DNA are 
obtained by dilution and then amplified with the ACTB primer (β-actin) and sample 
DNA concentration was calculated using the standard calibration curve. In comparison 
with these results the final genomic DNA concentrations of all the samples were 
normalized. 
ACTB primer: F: 5’GGCGGCACCACCATGTACCCT 3’ 
                     R: 5’AGGGGCCGGACTCGTCATACT 3’ 
Sodium bisulfite Reaction was performed on normal and cancerous DNA samples as well 
as standard methylated and unmethylated samples using the EZ DNA METHYLATION 
Gold Kit (Zymo Research, Irvine, CA)      
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5.1.1 Reagent preparation 
5.1.1.1 Preparation of CT-conversion Reagent: 
The CT conversion supplied is a solid mixture and 900µL water, 300 µl M-Dilution 
buffer and 50µl M-dissolving buffer to a tube of CT conversion Reagent. It is thoroughly 
mixed with frequent vortexing for 10 minutes. It can be stored at -20⁰C. 
It can also be prepared manually, 
Table 5.1 CT-conversion Reagent 
Reagent Composition Quantity 
96 samples 
Sodium metabisulphite Na2s2O5 5.8g 
M-Dilution buffer 2MNaOH 2880µL 
M-Dissolving buffer 50%dimethyl formamide 480µl 
water H2O 1200µl 
 
Light should be avoided a sit is very sensitive and best if used immediately after 
preparation. 
5.1.1.2 Preparation of M-wash buffer 
24ml of 100% ethanol to the 6ml M-wash buffer or 96ml of 100% ethanol to the 24ml M-
wash buffer concentrate should be added before use. 
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5.1.2 Protocol for bisulfite Conversion 
1. 130 µl of the CT conversion reagent prepared is added to 20µl of the DNA 
sample ion a PCR Tube. The amount of the input DNA can be from 500pg-2µg. 
However for optimum concentrations 200-500ng is preferred. 
2. If the DNA sample is less than 20µl, the difference can be made up by water. 
3. 2 or 3 µl of Salmon DNA is added to the sample. 
4. Place the sample tube in the thermo cycler and reaction proceeds in following 
steps 
        98⁰C for 10min 
        64⁰C for 150min 
        4⁰C storage up to 20 hours 
5. The whole process for purification consists of binding of sample, desulfonation, 
binding buffer wash, ethanol wash and elution. 
6. 600µl of the M-binding buffer is added to the zymo spin IC column and column is 
placed into a collection tube of capacity 800µl. 
7. The sample is added to the column and is inverted several times. It is centrifuged 
at full speed for 30s and flow through is discarded. 
8. 200µl of the M-desulphonation buffer is added to column and left a room 
temperature for 15-20min.After the incubation, it is centrifuged for 30s. 
9. 200µL of wash buffer is added twice and centrifuge after each for 30s. 
10. At the end the column is placed into a 1.5ml micro centrifuge tube and M-elution 
buffer (10Mm of Tris buffer) is added. It is centrifuged for 30s and DNA is eluted 
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DNA can be used immediately or stored at -20⁰C for further use. For longer time 
it should be stored below -70⁰C 
5.2 DNA Methylation Analysis 
MSP amplifications of 2genes p16 and SLIT-2 were performed on Real-Time PCR 
instrument .The primer sequences are mentioned in the table below, 
Table 5.2 The MSP primer sequences of genes 
Gene MSP primer 5’-3’ Annealing 
Temperature(⁰C) 
p16 F:TTATTAGAGGGTGGGGCGGATCGC
R:CCACCTAAATCGACCTCCGACCG 
66 
SLIT-2 F:GGGAGGCGGATTGTTTAG 
R:CATAACGCGCGAAAATACAC 
52 
 
5.2.1 Preparation of primer 
The initial concentration of the primer is 100µg.It is available in dry form. It is re-
suspended by dissolving in the appropriate amount of water. It is then diluted to 5µmol/L 
5.2.2 HRM master mix composition 
DNA polymerases, SYBR green dye, optimized concentration of Q-solution NTPs and 
MgCl2. The reaction mixture included 1µl of bisulfite –modified DNA, 5µl of HRM 
master mix 2x, 1µL primer solution at 5µmol/L and elution buffer to make up to 10µl. 
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The following PCR program was applied: 
95⁰Cdenaturing for 10min 
41 cycles of next three steps 
95⁰C for 45s. 
Annealing temperature for 30s 
Extension at72⁰C for 45s 
5.3 Standard Curve Analysis 
Standard Curve was prepared for the standard DNA sample which is bisulfite converted. 
The standard Curve was plotted at different concentrations and the concentrations were 
diluted with elution buffer. The concentrations used were 28ng/µl, 14ng/µl, 7ng/µl and 
3.5ng /µl. The Standard curve of ACTB-B (reference gene) with the CT plotted against 
the log of the starting quantity of template for each dilution. The same was done for p16 
and SLIT-2.The amplification efficiency and the R2 value were calculated.  
5.4 Sensitivity and Specificity of the primer 
The specificity of the MSP was determined by detecting both the methylated and 
unmethylated DNA modified with Bisulfite Conversion. The sensitivity of the MSP was 
determined by mixing various patterns of Methylated and Unmethylated Standard DNA 
like 1% methylated, 10%methylated, 100% methylated and 100% unmethylated. These 
percentages of methylated and unmethylated standard DNA were prepared by using 
different concentrations of methylated and Unmethylated DNA. 
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CHAPTER VI 
RESULTS AND DISCUSSION 
6.1 Standard curve analysis 
To determine the efficiency of the given gene the standard curves were plotted at 
different concentrations and R2 value was calculated. 
ACTB-B 
Table: 6.1 Standard Curve Analysis for the reference ACTB-B 
Conc.(ng/μl) Ct Melting temp(◦C) 
28 27.18 75.60 
14 28.24 75.40 
7 29.53 75.40 
3.5 30.92 75.60 
 
R2=0.996 
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P16 
Table: 6.2 Standard Curve Analysis for the gene p16 
conc (ng/µl) Ct Melting Temp(◦C) 
28 29.38 88.00 
14 31.53 88.00 
7 32.76 88.00 
3.5 33.72 88.00 
 
R2=0.964 
 
 
Figure 6.3: The standard Curve of p16 with the CT plotted against the log of 
the starting quantity of template for each dilution. 
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6.2 Gene specific methylation analysis 
During this epigenetic study of HCC aberrant promoter methylation of p16 and SLIT-2 
was reported in previous studies. These genes were selected for methylation screening. 
Four pairs of patient samples with considerable amount of DNA were selected and used 
in this methylation profiling. 
The methylation rates for the two genes were as followed, 
Table 6.4: The methylation profiles of the two genes 
Gene Cancerous liver tissue Non-Cancerous liver         
tissue 
 No of 
samples 
methylated 
Methylation 
rate 
No of 
samples 
methylated 
Methylation 
rate 
P16 0(4) 0 0(4) 0(4) 
SLIT-2 2(4) 50% 3(4) 75% 
 
6.3 Specificity and Sensitivity of the genes 
The specificity of the MSP methods on the two genes was evaluated using standard 
unmethylated and methylated DNA. This highly specific test on the reference gene and 
SLIT-2 was illustrated in the figure 6.7 and 6.8 below by the PCR amplification curve for 
each respectively. The selected primers and the optimized PCR conditions ensured that 
only methylated DNA after bisulfite conversion could be amplified for the two genes. 
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6.4 DISCUSSION 
Epigenetic Analysis of DNA Methylation plays a very important role in tumorigenesis 
and aid in the discovery of an efficient biomarker for the diagnosis, prognosis of 
Hepatocellular Carcinoma. In this study, we investigate the methylation status of SLIT-2 
and p16 in cancerous and noncancerous tissue samples. With each gene involved in 
different molecular pathways, p16 involved in the cell cycle Regulatory pathway and 
SLIT-2 involved in the beta –catenin-wnt signaling pathway. It is very important to 
understand their functions in Hepatocellular Carcinoma to predict the conditions for 
earlier diagnosis. 
Standard Curve Analysis was performed on various concentrations of genomic Standard 
DNA and graphs were plotted and R2 values were determined. Standard Curve Analysis 
was performed to determine the Amplification Efficiency of the PCR and they were 
determined for the reference gene, p16 and SLIT-2.The Standard Curve was plotted for 
log of starting quantity and Ct values .The correlation coefficient (R2) values determine 
the accuracy of the reaction and a good agreement between concentration and 
fluorescence. R2 values usually range from 0-1 with 1 being the best. The value of the 
reference gene ACTB-B was found to be 0.996, p16 was 0.964 and SLIT-2 was 0.980 
showing the efficiency of the MSP.  
In the present study alterations of the methylation status of p16 and SLIT-2, where 
sodium bisulfite react with methylated Cytosine’s specifically and aid in discrimination 
of methylated DNA by MSP. Gene specific alterations of promoter methylation status of 
SLIT-2 and P16 were investigated using bisulfite Conversion and MSP. Different pairs of 
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cancerous and noncancerous samples were tested and methylation status was examined. 
Initially all the samples were screened with ACTB-B which is a reference gene and only 
those samples which yielded positive results were further evaluated. P16 and SLIT-2 
methylation status were estimated by calculating the number of methylated samples over 
the total number of samples. Although hyper methylation of p16 was reported in earlier 
studies of HCC, the present study yielded negative results for all the pairs of samples. 
SLIT-2 showed methylation both in cancerous and non-Cancerous samples. 
In order to determine the efficiency of a gene as a Biomarker for Hepatocellular 
Carcinoma different categories have to be considered like specificity, sensitivity. The 
specificity of each gene was estimated on its ability to distinguish between unmethylated 
and methylated samples. It was found from the above results both p16 and SLIT-2 were 
specific enough as they did not give any signal for the Unmethylated Standard DNA and 
a positive signal was seen for the methylated DNA. The sensitivity of each gene was 
determined by its ability to determine various methylation percentages and we could see 
SLIT-2 showed signal with all the methylated percentages up to 1 whereas p16 did not 
give any signal for 1% methylated DNA. 
Though p16 which is one of the successful biomarker for HCC, it yielded negative results 
probably due to problems with its primer design. SLIT-2 yielded average results, thus 
making it useful as a biomarker. In conclusion, two genes were investigated for gene 
specific alterations through promoter methylation using bisulfite conversion and 
Methylation Specific PCR. In both cancerous and non-cancerous tissues CpG island 
hyper methylation was found in SLIT-2.In p16 no evident methylation was seen. 
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CHAPTER VII 
SUMMARY 
Cancerous and non-cancerous pairs of tissue samples were extracted from the FFPE 
tissues and samples are bisulfite converted where the positive display of 5-methyl 
cytosine’s in the gene promoter after bisulfite modification based on the selective 
reactivity of the sodium bisulfite to methylated and unmethylated Cytosine’s. The MSP is 
the method of DNA methylation Analysis used with analysis of methylation status of 
CpG islands with distinct methylation primer sets for the sequence of interest. p16, a gene 
involved in the cell cycle  Regulatory pathway and SLIT-2 involved in beta –catenin-wnt 
signaling pathway were evaluated as DNA methylation biomarkers based on 
amplification of the two genes on Real time PCR using Melting Curve Analysis. The 
samples were tested initially with the reference gene β-actin and Standard curves have 
been plotted for the genes of interest and the reference gene and R2 values were 
calculated. Gene promoter Methylation Analysis of the genes was done to analyze the 
methylation rate of both the genes in cancerous and non-cancerous samples. The 
specificity and sensitivity of each gene was assessed by using different methylation 
percentage.
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Thus, p16 yielded negative results and SLIT-2 moderate results as Biomarkers for HCC. 
The results from the present study show the role of DNA methylation as an important 
part of hepato-carcinogenesis and its importance as a Biomarker.
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